FGFR1 and neoplasm: From the tested drugs reported thus far, DNA-interfering trabectedin and the multi-tyrosine kinase inhibitors (TKIs) ponatinib, dasatinib, and nintedanib, as well as the more FGFR1-specific PD173074, showed pronounced activity against SFT tumor growth (Table 2).